VAERS Explorer
Back to explore

Report #2864990

Received Oct 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
82 yrs
State
NC
Recovered
Unknown
Vaccinated
Sep 22, 2025
Onset
—
Days to onset
—
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (AREXVY)GLAXOSMITHKLINE BIOLOGICALSUNK52Z52—

Symptoms (1)

Extra dose administered

Symptom narrative

Arexvy extra dose administration; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a female patient who received RSVPreF3 adjuvanted (Arexvy) (batch number 52Z52, expiry date 16-OCT-2025) for prophylaxis. Previously administered products included Arexvy (received unknown dose on an unknown date). On 22-SEP-2025, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced extra dose administered (Verbatim: Arexvy extra dose administration). The outcome of the extra dose administered was not applicable. Additional Information: GSK receipt date 23-SEP-2025 The reporter asked for safety or efficacy data on the administration of an extra dose of Arexvy. The reporter consented to follow up.